目的 探討復(fù)方夏天無片聯(lián)合氟桂利嗪治療偏頭痛患者的臨床療效。方法 選取南陽醫(yī)學(xué)高等?？茖W(xué)校第一附屬醫(yī)院2016年1月—2017年1月收治的偏頭痛患者161例，隨機分成對照組（80例）和治療組（81例）。對照組患者口服鹽酸氟桂利嗪膠囊，2粒/次，2次/d；治療組在對照組的基礎(chǔ)上口服復(fù)方夏天無片，2片/次，3次/d。兩組患者均治療2個月。觀察兩組患者臨床療效和復(fù)發(fā)率，比較治療前后兩組患者頭痛頻率和平均持續(xù)時間，VAS評分和降鈣素基因相關(guān)肽（CGRP）水平及不良反應(yīng)情況。結(jié)果 治療后，對照組患者臨床有效率為86.25%，顯著低于治療組的97.53%（P<0.05）；治療后，對照組復(fù)發(fā)率為15.00%，顯著高于治療組的3.70%（P<0.05）。治療后，兩組患者頭痛發(fā)作次數(shù)和頭痛平均持續(xù)時間均顯著下降（P<0.05），且治療組患者比對照組降低的更明顯（P<0.05）。治療后，兩組患者VAS評分和CGRP血清水平均顯著降低（P<0.05），且治療組VAS評分和血清CGRP水平明顯低于對照組（P<0.05）。治療期間，對照組患者的不良反應(yīng)發(fā)生率為13.75%，明顯高于治療組患者的3.70%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 復(fù)方夏天無片聯(lián)合氟桂利嗪治療偏頭痛療效顯著，安全性高，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical efficacy of Compound Xiatianwu Tablets combined with flunarizine in treatment of migraine. Methods Patients (161 cases) with migraine in the First Affiliated Hospital of Nanyang Medical College from January 2016 to January 2017 were randomly divided into control (80 cases) and treatment (81 cases). Patients in the control group were po administered with Flunarizine Hydrochloride Capsules, 2 grains/time, twice daily. Patients in the treatment group were po administered with Compound Xiatianwu Tablets on the basis of the control group, 2 tablets/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy and recurrence rate was evaluated, and the frequency and average duration of headache, the VAS score and CGRP level, the adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 86.25%, which was significantly lower than 97.53% in the treatment group (P < 0.05). After treatment, the recurrence rate in the control group was 15.00%, which was significantly higher than 3.70% in the treatment group (P < 0.05). After treatment, the frequency and average duration of headache in two groups was significantly decreased (P < 0.05). And the indexes in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the the VAS score and CGRP level in two groups was significantly decreased (P < 0.05). And these indexes in the treatment group were significantly lower than those in the control group (P < 0.05). During the treatment, the incidence of adverse reactions in the control group was 13.75%, which was significantly higher than 3.70% in the treatment group, with significant difference between two groups (P < 0.05). Conclusion Compound Xiatianwu Tablets combined with flunarizine has significant clinical efficacy in treatment of migrainewith high safety, which has a certain clinical application value.